talinolol has been researched along with simvastatin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bloomer, WD; Papadopoulou, MV; Rosenzweig, HS | 1 |
| Bernsdorf, A; Cascorbi, I; Giessmann, T; Haenisch, S; Hecker, U; Igelbrink, S; Modess, C; Siegmund, W; Terhaag, B; Wegner, D | 1 |
2 other study(ies) available for talinolol and simvastatin
| Article | Year |
|---|---|
The antitubercular activity of various nitro(triazole/imidazole)-based compounds.
Topics: Animals; Antitubercular Agents; Cell Line; Chlorocebus aethiops; Dose-Response Relationship, Drug; Humans; Imidazoles; Macrophages; Mice; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Nitro Compounds; Structure-Activity Relationship; Triazoles | 2017 |
Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Anticholesteremic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Drug Interactions; Duodenum; Female; Genotype; Humans; Infusions, Intravenous; Intestinal Mucosa; Liver-Specific Organic Anion Transporter 1; Male; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organic Anion Transporters; Polymorphism, Genetic; Propanolamines; RNA, Messenger; Simvastatin | 2006 |